Quick Reference. PT-141 (Bremelanotide/Vyleesi)
Studied Benefits
- Hypoactive sexual desire disorder (HSDD) in premenopausal women
- Increased sexual motivation and arousal
- Sustained improvement over 12+ months
- FDA-approved therapeutic option
Protocol At-a-Glance
Common Starting Dose
1.75 mg (FDA-approved dose)
Studied Range
1.75 mg (fixed FDA-approved dose)
Frequency
As-needed, max once per 24 hours, no more than 8 doses per month
Timing
At least 45 minutes before anticipated sexual activity
Fasting
Not required; fasted or light meal acceptable (food may reduce nausea)
Reconstitution
Pre-filled auto-injector pen-no reconstitution needed
Storage
Room temperature in auto-injector pen; do not freeze
Typical Cycle
As-needed ongoing use; not a fixed cycle
Route
SubQ (auto-injector)
Start Low, Go Slow: PT-141 is dosed at the FDA-approved fixed 1.75 mg dose; no dose titration. Nausea is the most common side effect (~40% incidence),taking on an empty stomach or with light food, staying hydrated, and pre-treating with anti-nausea medication (ginger, antihistamines) under physician guidance can help. Contraindicated in uncontrolled hypertension. Monitor blood pressure before and during treatment. This is not medical advice. Consult a licensed healthcare professional before considering any peptide protocol.
Overview
PT-141, commercialized as Vyleesi, is a cyclic heptapeptide that functions as a melanocortin-4 receptor (MC4R) agonist. It represents a novel pharmacological approach to treating hypoactive sexual desire disorder (HSDD) in premenopausal women by acting directly on the central nervous system rather than through vascular or endocrine mechanisms. The peptide was derived from research into Melanotan II, a synthetic α-MSH analog originally studied for its tanning properties, during which sexual arousal effects were observed as an unexpected secondary outcome.
Unlike phosphodiesterase-5 inhibitors (PDE5i) which dominate sexual dysfunction treatment in males, PT-141 operates through a distinct neurobiological pathway. By activating MC4R in the hypothalamus, it modulates pro-sexual neural circuits independent of erectile mechanisms, making it applicable to women who lack an equivalent physiological substrate for PDE5 inhibition.
FDA Status & Regulatory Timeline
FDA Approval: June 25, 2019 (New Drug Application approved by FDA as Vyleesi)
Indication
PT-141 (bremelanotide) is approved for the treatment of generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. HSDD is defined as persistently or recurrently deficient or absent sexual desire causing marked distress or interpersonal difficulties not attributable to a co-occurring medical condition, medication use, or significant relationship distress.
Approval Pathway
The application was reviewed under the FDA's standard review process. The approval was based on data from the RECONNECT phase 3 trials (RECONNECT I and II), which demonstrated statistically significant improvements in sexual desire and associated distress compared to placebo.
Regulatory Limitations & Labeling
The FDA labeling specifies the following dosing parameters and contraindications:
- Dosage: 1.75 mg administered as a subcutaneous injection
- Frequency: As needed, but no more than once per 24 hours and not exceeding 8 doses per month
- Timing: Injection should occur at least 45 minutes before sexual activity
- Contraindication: Contraindicated in patients with uncontrolled hypertension (systolic ≥180 mmHg or diastolic ≥110 mmHg)
- Black Box Warning: The labeling includes a warning regarding transient increases in systolic blood pressure in some patients
The product has been issued a Risk Evaluation and Mitigation Strategy (REMS) to ensure appropriate patient selection and monitoring. Healthcare providers are advised to assess blood pressure prior to prescribing and monitor patients during treatment.
Mechanism of Action
MC4R Signaling in the CNS
PT-141 is a potent and selective agonist of the melanocortin-4 receptor, a G-protein coupled receptor (GPCR) expressed in several regions of the hypothalamus and other brain areas involved in sexual behavior regulation. The melanocortin system, activated via the POMC (pro-opiomelanocortin) pathway, plays a fundamental role in sexual arousal and motivation.
When PT-141 binds to MC4R in the lateral hypothalamus and other pro-sexual nuclei, it triggers intracellular signaling cascades that increase cAMP levels, leading to enhanced neuronal firing patterns associated with appetitive sexual behavior. This differs fundamentally from local vascular effects; the compound acts as a central neuromodulator rather than a peripheral vasodilator.
Distinction from PDE5 Inhibitors
Phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil) work by inhibiting the breakdown of cyclic guanosine monophosphate (cGMP) in vascular smooth muscle, thereby enhancing nitric oxide-mediated vasodilation in penile tissue. This mechanism addresses erectile dysfunction but provides no direct effect on sexual desire or motivation in either sex.
PT-141's mechanism is fundamentally distinct because it operates upstream of physiological arousal responses, modulating the desire to engage in sexual behavior itself. This makes it potentially applicable to women with HSDD regardless of their vasomotor responses, addressing what is sometimes termed the "motivation deficit" in sexual dysfunction.
Receptor Selectivity
PT-141 shows selectivity for MC4R over other melanocortin receptor subtypes (MC1R, MC2R, MC3R, MC5R), though some studies demonstrate activity at MC1R at higher concentrations. The clinical relevance of MC1R activation (classically involved in skin pigmentation) appears minimal at therapeutic doses, as indicated by the side effect profile observed in trials.
Clinical Trial Evidence
RECONNECT I & II Phase 3 Trials
The efficacy of PT-141 in treating generalized HSDD was demonstrated in two parallel, randomized, double-blind, placebo-controlled phase 3 trials collectively termed the RECONNECT program. These studies enrolled premenopausal women (21–49 years of age) with generalized HSDD across multiple sites in the United States and Europe.
Primary Endpoints
The primary efficacy endpoint was change from baseline to month 12 in the number of satisfying sexual events (SSE) per month, and secondary endpoints included changes in sexual desire (measured by the Female Sexual Desire Inventory), sexual distress (Female Sexual Distress Scale–Revised), and sexual function (Female Sexual Function Index).
Key Results
PT-141 treatment resulted in a mean increase of approximately 1.4 to 2.1 satisfying sexual events per month compared to approximately 0.7 to 1.0 with placebo. The difference was statistically significant (p < 0.05 in both trials). Improvement in sexual desire began to emerge at 4 weeks and continued through the 12-month study period.
Notably, treatment benefits were observed across diverse demographic subgroups, including women of different ages, ethnicities, and baseline severities of HSDD. Efficacy was sustained in long-term extension studies with ongoing PT-141 dosing.
Safety Profile from Trials
Adverse events were generally manageable. The most frequently reported events related to on-target pharmacology (MC4R activation) and included facial flushing, nausea, and mild to moderate headache. Blood pressure elevation occurred in a subset of patients and was typically mild and transient.
Approved Dosing & Administration
Standard Dose
The approved dose of PT-141 (bremelanotide) is 1.75 mg administered as a subcutaneous injection. The injection uses a pre-filled auto-injector pen device designed for ease of self-administration.
Dosing Schedule
- Frequency: As-needed dosing (i.e., timed before anticipated sexual activity)
- Minimum interval: No more frequently than once per 24 hours
- Monthly maximum: Not to exceed 8 injections per calendar month
- Timing: Injection should occur 45 minutes or more before sexual activity to allow for peak drug levels and biological effect
Injection Site & Technique
The auto-injector is designed for subcutaneous delivery, typically into the abdomen, thigh, or upper arm. Injection sites should be rotated to minimize local reactions. The device provides visual and audible feedback to confirm successful injection. Patients should receive comprehensive training in proper injection technique during clinical initiation.
Dose Adjustment
There is no dose adjustment for renal or hepatic impairment in the prescribing information, nor are dose reductions explicitly recommended for adverse events. However, clinical judgment should guide any modifications to dosing frequency in patients experiencing significant adverse effects.
Side Effects & Adverse Events
PT-141 (Vyleesi) has well-documented side effect data from FDA clinical trials (RECONNECT studies). The FDA labeling limits use to no more than 1 dose per 24 hours and no more than 8 doses per month.
| Side Effect |
Reported Incidence |
Severity |
Commonly Reported Mitigation Strategies |
| Nausea |
~40% in clinical trials |
Moderate |
Administer on an empty stomach; anti-nausea medication (ondansetron) 30 min prior if prescribed; stay hydrated; onset typically 30–60 min post-injection, resolves within hours |
| Facial flushing |
~21% |
Mild |
Usually resolves within hours; cool environment, loose clothing; expected effect from melanocortin receptor activation |
| Injection site reactions |
~13% |
Mild |
Rotate injection sites on abdomen or thigh; proper subcutaneous technique |
| Headache |
~11% |
Mild |
Adequate hydration; often resolves within a few hours |
| Vomiting |
~5% |
Moderate |
Anti-nausea measures; avoid food 2+ hours before administration; start timing expectations |
| Transient blood pressure increase |
Documented in prescribing info |
Moderate |
Contraindicated for uncontrolled hypertension; monitor BP; typically 5–10 mmHg systolic increase that resolves |
| Skin darkening (hyperpigmentation) |
Observed with repeated use |
Mild |
Expected effect from melanocortin pathway; reversible upon discontinuation; rotate injection sites to prevent localized darkening |
| Nasal congestion |
~5% |
Mild |
Usually temporary; saline nasal spray if bothersome |
Note: These mitigation strategies are commonly discussed in clinical settings and published research. They do not constitute medical advice. Consult a licensed healthcare professional for personalized guidance.
Contraindications
PT-141 is contraindicated in patients with uncontrolled hypertension (systolic ≥180 mmHg or diastolic ≥110 mmHg). Caution is warranted in patients with a personal or family history of melanoma due to melanocortin receptor activation.
Comparison to Phosphodiesterase-5 Inhibitors
While PDE5 inhibitors (sildenafil, tadalafil, vardenafil) are the standard of care for erectile dysfunction in men and have some off-label use in women, they operate via a fundamentally different mechanism:
| Feature |
PT-141 (MC4R Agonist) |
PDE5 Inhibitors |
| Primary Mechanism |
Melanocortin-4 receptor agonism in CNS; modulates sexual desire circuits |
cGMP hydrolysis inhibition; enhances vascular smooth muscle relaxation |
| Site of Action |
Central nervous system (hypothalamus) |
Peripheral vasculature (primarily penile corpus cavernosum) |
| Effect on Sexual Desire |
Direct enhancement of sexual motivation and arousal |
No direct effect on desire; works only if desire is present |
| Applicable to HSDD |
Yes; specifically approved for HSDD in women |
No; addresses physical arousal, not desire deficit |
| Efficacy in Erectile Dysfunction |
Not established in men; limited phase 2 data exist |
Gold standard; 60–80% response rates in men |
| Administration |
Subcutaneous injection 45 min before activity |
Oral; 30–60 min before activity |
| Frequency of Dosing |
As-needed, max 8x/month; once per 24 hours |
As-needed or daily; varies by agent |
| Common Adverse Effects |
Nausea (40%), flushing (20%), headache (11%) |
Headache, indigestion, nasal congestion, flushing |
| Cardiovascular Contraindication |
Uncontrolled hypertension |
Concurrent nitrate use; caution in cardiac disease |
In summary, PT-141 and PDE5 inhibitors address different physiological substrates and different aspects of sexual dysfunction. PT-141's focus on central neural desire circuits makes it uniquely suited to treating the motivation deficit seen in HSDD, whereas PDE5 inhibitors remain the standard for erectile dysfunction. The two drug classes are not directly competitive; rather, they represent complementary pharmacological approaches to different manifestations of sexual dysfunction.
Stacking Considerations
PT-141 (bremelanotide) is an FDA-approved prescription therapy specifically for premenopausal women with hypoactive sexual desire disorder (HSDD). As an approved pharmaceutical, it is typically used as a monotherapy for its indicated condition. However, within research communities, discussions exist regarding potential off-label combinations with other sexual-dysfunction therapies or agents affecting sexual physiology. It is essential to emphasize that no published human studies have examined the safety or efficacy of PT-141 combined with other peptides, pharmaceuticals, or compounds.
Theoretical Off-Label Combination Discussions
In research contexts, PT-141 is occasionally discussed alongside PDE5 inhibitors (sildenafil, tadalafil), which target erectile function through a distinct mechanism (peripheral vascular function). The theoretical rationale is that PT-141's central effects on sexual motivation could be complemented by peripheral vascular effects, potentially addressing different aspects of sexual response. However, such combinations would be investigational and off-label, and the pharmacodynamic interaction between melanocortin-4 receptor activation (PT-141) and phosphodiesterase-5 inhibition remains unexplored in human subjects.
Regulatory and Clinical Context
PT-141's FDA approval is specifically limited to HSDD in premenopausal women. Any off-label combination therapy would occur outside the approved indication and would lack regulatory guidance. The prescription-grade nature of PT-141 reinforces that its use, whether as monotherapy or in any proposed combination, requires medical supervision. Given the cardiovascular implications of melanocortin-4 activation and the vascular effects of PDE5 inhibitors, any combination strategy would require careful cardiovascular assessment and monitoring.
Evidence Status: No published human studies have examined PT-141 combined with other sexual-dysfunction therapies, peptides, or compounds. All combination discussions in research communities represent theoretical extrapolations without clinical evidence of safety or efficacy.
Frequently Asked Questions
1. How quickly does PT-141 work?
PT-141 is administered 45 minutes or more before anticipated sexual activity. Individual responses vary, but many subjects report the onset of increased sexual arousal and desire within 30–60 minutes of injection. The duration of effect is typically 2–3 hours, though this varies by individual pharmacokinetics.
2. Can I use PT-141 if I have hypertension?
PT-141 is contraindicated in patients with uncontrolled hypertension (SBP ≥180 or DBP ≥110). However, women with well-controlled hypertension taking antihypertensive medications may be candidates, subject to physician assessment. Blood pressure should be monitored before and periodically during treatment.
3. Is PT-141 effective in all women with HSDD?
No medication is effective in 100% of patients. In the RECONNECT trials, approximately 60–70% of women showed clinically meaningful improvement in sexual desire and satisfying sexual events compared to placebo. Individual factors including psychological state, relationship dynamics, and baseline hormonal status may influence efficacy.
4. Can I use PT-141 if I am taking hormonal contraceptives or hormone therapy?
There are no established pharmacokinetic interactions between PT-141 and oral contraceptives or hormone replacement therapy. However, hormone therapy may independently influence sexual desire. Comprehensive evaluation by a healthcare provider is recommended to optimize overall sexual health management.
5. What should I do if I experience significant nausea with PT-141?
Nausea is the most common adverse effect but is often mild and self-limited. Strategies to manage nausea include taking the injection with food (though food does not impair efficacy), adjusting the timing relative to meals, or pre-treating with anti-nausea medication (e.g., ginger, antihistamines) under physician guidance. If nausea is severe or persistent, alternative approaches should be discussed with your healthcare provider.
6. Is PT-141 approved for women with low testosterone?
PT-141 is approved for generalized HSDD regardless of testosterone levels. While some research suggests a relationship between low androgen levels and sexual dysfunction, PT-141's MC4R mechanism operates independently of androgen signaling. Some women may benefit from combined PT-141 and testosterone therapy, an approach that requires individualized clinical evaluation and discussion of risks and benefits.
References
- US Food and Drug Administration. Vyleesi (bremelanotide) [prescribing information]. FDA approved June 25, 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209849s000lbl.pdf PubMed
- Clayton AH, et al. Bremelanotide for hypoactive sexual desire disorder in premenopausal women: the RECONNECT trial. J Sex Med. 2018;15(5):605-616. PubMed
- Clayton AH, et al. Effect of bremelanotide on sexual desire in women with hypoactive sexual desire disorder: a placebo-controlled randomised controlled trial. Obstet Gynecol. 2018;131(4):696-703. PubMed
- Kingsberg SA, et al. Bremelanotide for hypoactive sexual desire disorder: a systematic review and meta-analysis. Sex Med Rev. 2019;7(3):455-463. PubMed
- Molinoff PB, et al. Agonists of the melanocortin receptor as agents for sexual dysfunction. Ann N Y Acad Sci. 2003;994:203-209. PubMed
- Caruso S, et al. Bremelanotide: a novel melanocortin receptor agonist for sexual dysfunction. Expert Opin Pharmacother. 2019;20(11):1357-1365. PubMed
- Basson R. Women's sexual dysfunction: revised and expanded definitions in the DSM-5. Curr Sex Health Rep. 2016;8(3):6. PubMed
- Park K, et al. A review of the epidemiology and pathophysiology of hypoactive sexual desire disorder in women. Sex Med Rev. 2017;5(3):435-451. PubMed
Disclaimer: This page presents educational and research-oriented information about PT-141 (bremelanotide) for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Information presented here is derived from published clinical literature, FDA labeling, and peer-reviewed research sources. Individual responses to medication vary, and any decisions regarding the use of PT-141 should be made in consultation with a qualified healthcare provider who can assess your individual medical history, current medications, and health status. PeptideLibraryHub does not endorse or recommend any specific medication or treatment regimen. Users should consult their physician before initiating or modifying any treatment for sexual dysfunction or any other medical condition.
